Table 2 Medicines which have the ability to overcome resistance to treatment in CML
From: The importance of personalized medicine in chronic myeloid leukemia management: a narrative review
Medicine name | Mechanism | Combination with TKIs or chemotherapies | References |
|---|---|---|---|
Ruxolitinib | Inhibition of STAT-5 activity | Nilotinib | [246] |
bardoxolone methyl (CDDO-Me) | Inhibition of STAT-3 activity | Â | [247] |
BP-5-087 | Inhibition of STAT-3 activity | IMA | [248] |
Everolimus (RAD001) | mTOR inhibitor | Â | [177] |
NVP-BEZ235 | mTOR inhibitor | Â | [249] |
Pictilisib (GDC-0941) | PI3K inhibitor | Dastatinib | [179] |
LY294002 | PI3K inhibitor | IMA | |
trametinib (GSK1120212) | MEK inhibitor | IMA | [181] |
U0126 | MEK inhibitor | Dastatinib/IMA | [252] |
PD184352 | MEK inhibitor | Â | |
Wortmannin | PI3K inhibitor | IMA | [255] |
INNO-406 | inhibit Pgp export pump | Cyclosporin A | [256] |
MK-0457 (VX-680) | Aurora A, B and C kinase inhibitor | Â | [257] |
Tipifarnib (R115777) | Ras farnelysation inhibitor | IMA | |
Lonafarnib (SCH66336) | Ras farnelysation inhibitor | Â | [261] |
BMS-214662 | Ras farnelysation inhibitor | Â | [253] |
17-allylamino-17-demethoxygeldanamycin | Pgp pump inhibitor and Hsp90 inhibitor | IMA |